Orphan designation was granted by the FDA to Curis (CRIS) Inc’s emavusertib for the treatment of primary central nervous system lymphoma, according to a post to the agency’s website.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.